FutureFuel Corp is a United States-based manufacturer operating two business segments from its integrated facility in Batesville, Arkansas. Its Chemicals segment produces custom and performance specialty chemicals, providing highly engineered manufacturing solutions to a diversified base of industrial and specialty customers. Its Biofuels segment manufactures and markets biodiesel and related co-products, supported by storage, logistics, and distribution assets that serve North American renewable fuel markets.
Investors follow FF for its dual exposure to renewable fuel demand, which is shaped by federal blending obligations and tax incentives, and to specialty chemical manufacturing, which benefits from long-term customer relationships and domestic reshoring trends. The company's flexible, multi-feedstock production platform is a key competitive strength, allowing it to process a broad range of renewable feedstocks as input costs shift. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, FF shares declined approximately 47%, falling from a closing price of about $5.56 in late October to near $2.94. The move was not gradual: the stock traded in the $5.40 to $5.80 range through much of late October before a sharp downward break in mid-November.
The quarterly picture is similar in magnitude. Three months earlier, shares traded near $5.58, meaning the stock also lost roughly 47% over the quarter. In practice, the stock was relatively range-bound through most of the quarter and then repriced sharply lower following the company's third-quarter earnings release, which compressed the bulk of the decline into a short window rather than a steady multi-month downtrend.
The dominant catalyst was FutureFuel's third-quarter 2026 results, reported after the close of trading in early November. While revenue surged 361% year over year to $104.7 million, the company remained unprofitable, recording a net loss of $8.4 million, or $0.19 per diluted share, and a negative adjusted EBITDA of $4.9 million.
Several factors explain why strong top-line growth failed to support the share price. Biofuels revenue rose to $87.8 million from $7.1 million a year earlier on higher volumes and pricing, but those gains were offset by elevated input costs, with soybean oil and other feedstocks trading near all-time highs. The quarter also included derivative and hedging losses of roughly $8.7 million, pressuring margins. In the Chemicals segment, extended maintenance and a customer inventory rebalance temporarily reduced throughput. The combination of continued losses, compressed margins, and a decline in cash and equivalents from $34.3 million at midyear to $21.3 million at quarter-end outweighed the revenue momentum, triggering the sharp selloff.
Across the quarter, the broader narrative was one of improving demand offset by persistent profitability challenges. Biofuels capacity utilization climbed to 83% in the third quarter from 56% in the second quarter, supported by greater regulatory clarity and record renewable volume obligation levels. Chemicals results also improved on a gross-profit basis, aided by higher volumes and new customer programs.
However, input cost inflation, derivative losses, and a working-capital-driven reduction in cash kept the company in a loss-making position. Management's commentary pointed to near-term improvement, including guidance for roughly $7 million in fourth-quarter adjusted EBITDA and positive adjusted EBITDA for full-year 2026, but the market's reaction to the latest quarterly figures indicated that investors remain focused on the gap between revenue growth and bottom-line profitability. From what I see, this disconnect between top-line momentum and profitability is worth monitoring closely.
Several factors are likely to shape FF's path in the coming quarters. First, execution against the company's guidance for positive fourth-quarter and full-year 2026 adjusted EBITDA will be closely watched. Second, feedstock costs remain a swing factor: management has noted early signs of moderation in soybean oil and other inputs, and sustained easing could support biofuel margins. Third, a regulatory change scheduled for early 2027 is expected to narrow the renewable diesel equivalency advantage, potentially improving the competitive position of biodiesel producers.
On the chemicals side, investors may monitor the ramp of a new European reshoring customer expected to begin batch production in early 2027, as well as a low-cost refined glycerin expansion that management estimates could add $5 million to $10 million in annual profit. Liquidity management, working capital needs, and the pace of cash preservation will also remain important given the decline in cash during the quarter. As always, these forward-looking factors carry uncertainty and should be evaluated alongside the company's actual reported results. I’m watching this closely as the next few quarters unfold.
In my view, systematic approaches can help cut through the noise around names like FF. I often turn to Tickeron’s AI tools when reviewing how individual stocks fit into broader industry patterns or when testing ideas against historical data. One platform I find useful is the AI Trading Bots, which lets users explore automated strategies across thousands of tickers without building everything from scratch. It has been a practical way for me to compare performance metrics and see which models align with current market conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where FF declined for three days, in 182 of 255 cases, the price declined further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FF as a result. In 58 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for FF turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 25 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
FF moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FF crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where FF advanced for three days, in 195 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
FF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 139 of 193 cases where FF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (2.284). P/E Ratio (-8.867) is within average values for comparable stocks, (-17.137). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (1.548). Dividend Yield (0.008) settles around the average of (0.039) among similar stocks. P/S Ratio (1.553) is also within normal values, averaging (48.960).
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. FF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of specialty chemicals and biofuels
Industry ChemicalsSpecialty